Strategic Advantages Include Immediate Regulatory Compliance and Validation with European FSA’s Novel Foods Application

LONDON, U.K. — March 22, 2021 — Turnkey CBD formulator, private label accelerator, and  product distributor Taylor Mammon announced today that the company, established in  2018, was acquired by US-based GenCanna, a leading producer of hemp-derived, THC-free, premium CBD and other cannabinoids. The move culminates the evolution of a successful  three-year relationship, in which GenCanna served, and will continue to serve, as Taylor  Mammon’s primary source of CBD and other cannabinoids for infusion into brand products.

The acquisition comes on the heels of an 18-month initiative at Taylor Mammon to prepare for its Novel Foods Application, a process GenCanna has supported every step of the way. Taylor Mammon’s union with GenCanna has not only fast-tracked this compliance milestone, but now narrows the borders between the US and the UK, positioning Taylor Mammon as a full-service, vertically integrated, worldwide CBD gateway. Taylor Mammon  can now offer its current and future brand partners CBD infusion services that are immediately and fully compliant to the stringent regulatory mandates dictated under two Novel Foods Applications — one for the Food Safety Authority (“FSA”) of the United Kingdom and one for its European equivalent, the EFSA — meeting the deadline for validation of March 31, 2021.

“We are delighted with the opportunity this acquisition affords us,” said Nathan Wogman, co-founder and Managing Director of Taylor Mammon. “GenCanna’s acquisition of Taylor Mammon positions us for significant international growth and to be a global leader in the CBD arena. Our partnership provides us with the financial and intellectual capital and discipline to accelerate our growth through product innovation, contract manufacturing, fulfillment, and distribution services.”

Between the UK’s increasing understanding and embracing of THC-free CBD infusion into consumable and topical goods, the validation deadline for novel foods compliance now around the corner, and the bridging of a CBD market product and supply chain between the UK and the US, the timing of this union is ideal.

“As one of our long-term and valued customers, we admired Taylor Mammon’s philosophy and approach to CBD,” said GenCanna CEO, Andrew Barnett. “This alliance — which we understand is the first of its kind for a UK-based CBD company — drives unique and mutually beneficial operational and marketing synergies that will catapult product development, sales, and revenue opportunities within our respective geographies.”

About Taylor Mammon
Based in the U.K., Taylor Mammon Ltd. (taylormammon.com) is a white label manufacturer and brand distributor of CBD-infused goods. Taylor Mammon sees the benefits in the power of CBD and has created a business model that affords its brand partners total ownership over their brands, while enabling end consumers to benefit from the exciting applications of CBD. Taylor Mammon continually innovates new products to meet its partners’ rigorous demands.

UK Contact: Nathan Wogman
Managing Director, Taylor Mammon
0208.344.2005
[email protected]

About GenCanna
Based in the U.S., GenCanna is a vertically integrated pioneer-producer of premium hemp derived CBD and other cannabinoids in both bulk supply as well as in high-quality finished goods formulations. GenCanna’s optimized supply chain is built and operated under the strictest quality assurance standards and regulatory mandates (BRCGS, cGMP), and the company continues to achieve the industry’s most sought after compliance validations, including the European FSA’s Novel Foods Application. Learn more at gencanna.com/compliance.

US Contact: Andrew G. Barnett
CEO, GenCanna
203.972.1718
[email protected]

# #